{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:48:21Z","timestamp":1648810101375},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1245\/s10434-019-08013-3","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T16:16:58Z","timestamp":1575303418000},"page":"735-736","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ASO Author Reflections: The Past, Present, and Future of Managing Melanoma Lymph Node Metastases: What the Trials Tell Us"],"prefix":"10.1245","volume":"27","author":[{"given":"Danielle M.","family":"Bello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B.","family":"Faries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"issue":"4","key":"8013_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","volume":"127","author":"DL Morton","year":"1992","unstructured":"Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392\u201399.","journal-title":"Arch Surg."},{"issue":"7","key":"8013_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. New Engl J Med. 2014;370(7):599\u2013609.","journal-title":"New Engl J Med."},{"key":"8013_CR3","doi-asserted-by":"publisher","unstructured":"Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol. Epub 18 Sep 2019. https:\/\/doi.org\/10.1245\/s10434-019-07830-w.","DOI":"10.1245\/s10434-019-07830-w"},{"issue":"6","key":"8013_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757\u201367.","journal-title":"Lancet Oncol."},{"issue":"23","key":"8013_CR5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322.","journal-title":"N Engl J Med."},{"issue":"11","key":"8013_CR6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480\u201392.","journal-title":"Lancet Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-08013-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-08013-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-08013-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:03:54Z","timestamp":1606694634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-08013-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":6,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8013"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-08013-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]},"assertion":[{"value":"14 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Bello has worked as a consultant for survivornet. Dr. Faries serves on advisory boards for Novartis, Pulse Bioscience, and Bristol-Myers Squibb, and is a consultant for Delcath Systems.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}